Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models

An efficacious HIV vaccine is urgently needed to curb the AIDS pandemic. The modest protection elicited in the phase III clinical vaccine trial in Thailand provided hope that this goal might be achieved. However, new approaches are necessary for further advances. As HIV is transmitted primarily acr...

Full description

Bibliographic Details
Main Authors: Iskra Tuero, Marjorie Robert-Guroff
Format: Article
Language:English
Published: MDPI AG 2014-08-01
Series:Viruses
Subjects:
Online Access:http://www.mdpi.com/1999-4915/6/8/3129
id doaj-16b14cab120a4bd8ae8de8efac03e675
record_format Article
spelling doaj-16b14cab120a4bd8ae8de8efac03e6752020-11-24T22:59:20ZengMDPI AGViruses1999-49152014-08-01683129315810.3390/v6083129v6083129Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate ModelsIskra Tuero0Marjorie Robert-Guroff1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAAn efficacious HIV vaccine is urgently needed to curb the AIDS pandemic. The modest protection elicited in the phase III clinical vaccine trial in Thailand provided hope that this goal might be achieved. However, new approaches are necessary for further advances. As HIV is transmitted primarily across mucosal surfaces, development of immunity at these sites is critical, but few clinical vaccine trials have targeted these sites or assessed vaccine-elicited mucosal immune responses. Pre-clinical studies in non-human primate models have facilitated progress in mucosal vaccine development by evaluating candidate vaccine approaches, developing methodologies for collecting and assessing mucosal samples, and providing clues to immune correlates of protective immunity for further investigation. In this review we have focused on non-human primate studies which have provided important information for future design of vaccine strategies, targeting of mucosal inductive sites, and assessment of mucosal immunity. Knowledge gained in these studies will inform mucosal vaccine design and evaluation in human clinical trials.http://www.mdpi.com/1999-4915/6/8/3129HIV vaccinemucosal immunitynon-human primate
collection DOAJ
language English
format Article
sources DOAJ
author Iskra Tuero
Marjorie Robert-Guroff
spellingShingle Iskra Tuero
Marjorie Robert-Guroff
Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
Viruses
HIV vaccine
mucosal immunity
non-human primate
author_facet Iskra Tuero
Marjorie Robert-Guroff
author_sort Iskra Tuero
title Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
title_short Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
title_full Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
title_fullStr Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
title_full_unstemmed Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
title_sort challenges in mucosal hiv vaccine development: lessons from non-human primate models
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2014-08-01
description An efficacious HIV vaccine is urgently needed to curb the AIDS pandemic. The modest protection elicited in the phase III clinical vaccine trial in Thailand provided hope that this goal might be achieved. However, new approaches are necessary for further advances. As HIV is transmitted primarily across mucosal surfaces, development of immunity at these sites is critical, but few clinical vaccine trials have targeted these sites or assessed vaccine-elicited mucosal immune responses. Pre-clinical studies in non-human primate models have facilitated progress in mucosal vaccine development by evaluating candidate vaccine approaches, developing methodologies for collecting and assessing mucosal samples, and providing clues to immune correlates of protective immunity for further investigation. In this review we have focused on non-human primate studies which have provided important information for future design of vaccine strategies, targeting of mucosal inductive sites, and assessment of mucosal immunity. Knowledge gained in these studies will inform mucosal vaccine design and evaluation in human clinical trials.
topic HIV vaccine
mucosal immunity
non-human primate
url http://www.mdpi.com/1999-4915/6/8/3129
work_keys_str_mv AT iskratuero challengesinmucosalhivvaccinedevelopmentlessonsfromnonhumanprimatemodels
AT marjorierobertguroff challengesinmucosalhivvaccinedevelopmentlessonsfromnonhumanprimatemodels
_version_ 1725644843289411584